Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

Maraviroc Failure with Co-receptor Switch Does Not Lead to HIV Disease Progression

People with HIV strains that switch from CCR5 to CXCR4 co-receptor use during treatment with the CCR5 antagonist maraviroc (Selzentry) do not experience adverse outcomes including subsequent treatment failure or HIV disease progression, according to findings from the MERIT study presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.

Read more:

Use of CCR5 Antagonist Does Not Explain Better CD4 Cell Recovery with Newer Antiretroviral Drugs

HIV positive people using today's state-of-the-art antiretroviral drugs are likely to achieve good CD4 cell recovery, but this cannot be attributed specifically to use of CCR5 antagonists such as maraviroc (Selzentry), according to a presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) this week in Boston.

Read more:

Revised Raltegravir (Isentress) Label Adds 96 Week Data

The U.S. Food and Drug Administration (FDA) this week announced that the product label information for the integrase inhibitor raltegravir (Isentress) has been updated to include longer-term safety and efficacy data from the STARTMRK (021) trial of people starting antiretroviral therapy for the first time, and the BENCHMRK 1 and 2 (018 and 019) trails of treatment-experienced patients. Raltegravir remained potent over 2 years with no notable long-term safety concerns.

Read more:

Meta-analysis Finds Tenofovir Linked to Modest Kidney Impairment, No Increase in Bone Fractures

Use of tenofovir (Viread, also in the Truvada and Atripla combination pills) was found to be associated with statistically significant loss of kidney function in a systematic review and meta-analysis, but this was considered to have only a modest clinical impact, researchers reported in the September 15, 2010 issue of Clinical Infectious Diseases. This review also found no link between tenofovir and bone fractures. Researchers concluded that tenofovir use does not need to be limited in areas where kidney function cannot be adequately monitored.

FDA Updates Etravirine (Intelence) Label with Additional Information on Drug Interactions

The U.S. Food and Drug Administration (FDA) last week announced that the product label for the next-generation NNRTI etravirine (Intelence) has been updated to include new information about drug-drug interactions with the boosted protease inhibitor lopinavir/ritonavir (Kaletra), the antifungal agents fluconazole (Diflucan) and voriconazole (VFEND), and the anti-clotting medication clopidogrel (Plavix).


Read more: